β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma

Wang,Zheng; Sheng,Yuan‑Yuan; Gao,Xiao‑Mei; Wang,Chao‑Qun; Wang,Xiang‑Yu; Lu,Xu; Wei,Jin‑Wang; Zhang,Kai‑Li; Dong,Qiong‑Zhu; Qin,Lun‑Xiu

doi:10.3892/mco.2015.569

β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma

Authors:
- Zheng Wang
- Yuan‑Yuan Sheng
- Xiao‑Mei Gao
- Chao‑Qun Wang
- Xiang‑Yu Wang
- Xu Lu
- Jin‑Wang Wei
- Kai‑Li Zhang
- Qiong‑Zhu Dong
- Lun‑Xiu Qin
View Affiliations

Affiliations: Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China
Published online on: May 15, 2015 https://doi.org/10.3892/mco.2015.569
Pages: 936-940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The β-catenin gene is frequently mutated in patients with hepatocellular carcinoma (HCC) and has long been thought to be one of the major oncogenes involved in the hepatocarcinogenesis. The prognostic role of β‑catenin mutation in HCC remains unclear. To address this issue, a search for relevant studies was performed in the PubMed, Embase and Web of Science databases. The pooled effect was calculated from the available data to evaluate the correlation of β‑catenin mutation with overall survival rate and tumor clinicopathological features in patients with HCC. The pooled odds ratio (OR) was calculated using the Mantel‑Haenszel model for fixed effects. Three studies met the inclusion criteria. A total of 618 cases were included, and β‑catenin mutation was identified in 104 of them. The meta‑analysis revealed that the presence of β‑catenin mutation (n=104), compared with the control group (n=514), was correlated with a longer overall survival rate [OR, 0.33; 95% confidence interval (CI), 0.21‑0.53; P<0.00001] in patients with HCC. No significant heterogeneity was found among the eligible studies (I2=0%; P=0.72). β‑catenin mutation was correlated with a relatively lower rate of hepatitis B virus infection (OR, 0.36; 95% CI, 0.21‑0.61; P=0.0002), improved tumor differentiation (OR, 0.32; 95% CI, 0.19‑0.56; P<0.0001) and a lower tumor‑node‑metastasis stage (I+II) (OR, 0.23; 95% CI, 0.14‑0.38; P<0.00001). These findings suggest that β‑catenin mutation may predict a favorable prognosis in patients with HCC.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
2	Maluccio M and Covey A: Recent progress in understanding, diagnosing and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
5	Ming L, Thorgeirsson SS, Gail MH, et al: Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 36:1214–1220. 2002. View Article : Google Scholar : PubMed/NCBI
6	Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL and Lok AS: Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 42:218–224. 2005. View Article : Google Scholar : PubMed/NCBI
7	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
8	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
9	Garraway LA and Lander ES: Lessons from the cancer genome. Cell. 153:17–37. 2013. View Article : Google Scholar : PubMed/NCBI
10	Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 13:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
11	Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007. View Article : Google Scholar : PubMed/NCBI
12	Grigoryan T, Wend P, Klaus A and Birchmeier W: Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 22:2308–2341. 2008. View Article : Google Scholar : PubMed/NCBI
13	Miyoshi Y, Iwao K, Nagasawa Y, et al: Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58:2524–2527. 1998.PubMed/NCBI
14	Taniguchi K, Roberts LR, Aderca IN, et al: Mutational spectrum of beta-catenin, AXIN1 and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 21:4863–4871. 2002. View Article : Google Scholar : PubMed/NCBI
15	Elmileik H, Paterson AC and Kew MC: Beta-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma. J Surg Oncol. 91:258–263. 2005. View Article : Google Scholar : PubMed/NCBI
16	Laurent-Puig P and Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene. 25:3778–3786. 2006. View Article : Google Scholar : PubMed/NCBI
17	Fujimoto A, Totoki Y, Abe T, et al: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kan Z, Zheng H, Liu X, et al: Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23:1422–1433. 2013. View Article : Google Scholar : PubMed/NCBI
19	Harada N, Oshima H, Katoh M, Tamai Y, Oshima M and Taketo MM: Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 64:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
20	Tward AD, Jones KD, Yant S, et al: Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 104:14771–14776. 2007. View Article : Google Scholar : PubMed/NCBI
21	Laurent-Puig P, Legoix P, Bluteau O, et al: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 120:1763–1773. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hoshida Y, Nijman SM, Kobayashi M, et al: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
23	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
24	Gough NR: Focus issue: Wnt and beta-catenin signaling in development and disease. Sci Signal. 5:eg22012. View Article : Google Scholar : PubMed/NCBI
25	Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL and Peng SY: Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 157:763–770. 2000. View Article : Google Scholar : PubMed/NCBI
26	Yuan RH, Jeng YM, Hu RH, et al: Role of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 15:321–329. 2011. View Article : Google Scholar : PubMed/NCBI
27	Mao TL, Chu JS, Jeng YM, Lai PL and Hsu HC: Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread and good prognosis. J Pathol. 193:95–101. 2001. View Article : Google Scholar : PubMed/NCBI
28	Han ZG: Functional genomic studies: Insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet. 13:171–205. 2012. View Article : Google Scholar : PubMed/NCBI
29	Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F and Slattery ML: Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 59:1442–1444. 1999.PubMed/NCBI
30	Gamallo C, Palacios J, Moreno G, Calvo DMJ, Suarez A and Armas A: Beta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta-catenin gene mutations, clinicopathological features and clinical outcome. Am J Pathol. 155:527–536. 1999. View Article : Google Scholar : PubMed/NCBI
31	Sekine S, Lan BY, Bedolli M, Feng S and Hebrok M: Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology. 43:817–825. 2006. View Article : Google Scholar : PubMed/NCBI
32	Sekine S, Gutierrez PJ, Lan BY, Feng S and Hebrok M: Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology. 45:361–368. 2007. View Article : Google Scholar : PubMed/NCBI
33	Apte U, Zeng G, Muller P, et al: Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology. 44:992–1002. 2006. View Article : Google Scholar : PubMed/NCBI
34	Harada N, Miyoshi H, Murai N, et al: Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 62:1971–1977. 2002.PubMed/NCBI
35	Guichard C, Amaddeo G, Imbeaud S, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
36	Li M, Zhao H, Zhang X, et al: Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 43:828–829. 2011. View Article : Google Scholar : PubMed/NCBI